SN-38 is the molecular reason an irinotecan prodrug can become a far more potent topoisomerase I inhibitor inside the body.
Ropivacaine turned stereochemistry into a design tool for retaining long local anesthesia while improving the therapeutic profile.
The echinocandin B nucleus shows how fermentation and semisynthesis can share the work of building a complex modern antifungal medicine.
Papaverine is an opium alkaloid whose story is defined not by opioid action, but by direct smooth-muscle relaxation.
Epinephrine bitartrate links one of physiology's classic signaling molecules to the precise salt chemistry required for dependable pharmaceutical use.
Isoproterenol helped transform adrenergic pharmacology from a broad physiological effect into the language of receptor subtypes.
Chloroprocaine's rapid hydrolysis turned a procaine modification into a local anesthetic distinguished by brevity of action.
Small synthetic intermediates can sit quietly behind the construction of medicinal chemistry's most elaborate ring systems.
Rezafungin turned echinocandin chemistry toward a long-acting design compatible with once-weekly intravenous dosing.
DXd embodies the ADC idea: separate targeting from cytotoxic power, then reconnect them through molecular engineering.
A terphenyl acid becomes valuable not as a drug itself, but as the engineered side chain of a far more complex antifungal molecule.
Norepinephrine bitartrate shows how a physiological signal becomes a precisely defined pharmaceutical salt for emergency medicine.
In pharmaceutical process chemistry, an intermediate can be essential to a medicine without ever being the medicine itself.
Voclosporin shows how a one-carbon medicinal-chemistry change can reshape the performance of a celebrated natural-product-derived scaffold.
Prodrug design is molecular logistics: temporarily mask a troublesome functional group, improve delivery, then let metabolism uncover the active drug.
Sitagliptin's story starts with hormone metabolism: understand why GLP-1 disappears so quickly, then design a small molecule to slow that process.
First came a useful drug, then its molecular target, then a stronger ligand. Brivaracetam is a clear example of mechanism guiding next-generation drug design.
Fimasartan shows how a mature drug class can still evolve: keep a validated biological target, redesign the molecular scaffold, and search for a better overall pharmacological balance.
A next-generation antibiotic does not always need a new target. Tigecycline shows how redesigning an old scaffold can address resistance.
Drug chemistry does not end with the active molecule. Entecavir monohydrate shows the difference between pharmacological identity and solid-state identity.
One water molecule can justify a separate material identity. Tenofovir monohydrate shows why crystal chemistry matters alongside medicinal chemistry.
Tenofovir is both an antiviral story and a drug-delivery story: the group needed for biochemical activity is also the group that makes oral delivery difficult.
Today's Chemical Story: Disodium pyrophosphate — one molecular feature, one real-world consequence.
(-)-beta-Citronellol is a reminder that small structural details can have large practical consequences.
Why does 3-Hydroxy-2-butanone matter? Its most interesting chemistry is easier to remember than a list of uses.
Potassium sorbate is a reminder that small structural details can have large practical consequences.
Why does ham stay pink after cooking while ordinary pork turns gray-brown? Sodium nitrite isn't simply coloring the meat—the real story happens around an iron atom already inside it.
What connects mold-resistant bread with the holes in Swiss cheese? Surprisingly, part of the answer is the same three-carbon acid: propionic acid.